Foxtons Group — Q125 benefit from Stamp Duty pull forward

Foxtons Group (LSE: FOXT)

Last close As at 29/04/2025

GBP0.59

−0.90 (−1.50%)

Market capitalisation

GBP180m

More on this equity

Research: Real Estate

Foxtons Group — Q125 benefit from Stamp Duty pull forward

Foxtons Group’s Q125 trading update revealed revenue growth of 24%, driven predominantly by growth in the Sales division, which in turn benefited from a pull forward in transactions due to Stamp Duty changes. However, in the longer term, we believe the company’s strategic direction remains positive, and we expect an update on its strategy to be revealed at the 4 June capital markets day. This may see an upgrade to the medium-term adjusted operating profit target of £28–33m, which is now coming into focus. We maintain our revenue and operating profit estimates and our 134p/share valuation, although risks appear to be skewed to the upside if market momentum continues.

Andy Murphy

Written by

Andy Murphy

Director of content, industrials

Real estate

Q125 trading update

23 April 2025

Price 57.30p
Market cap £172m

Net cash/(debt) at 31 December 2024

£(12.7)m

Shares in issue

300.4m
Free float 100.0%
Code FOXT
Primary exchange LSE
Secondary exchange N/A
Price Performance
% 1m 3m 12m
Abs (7.4) (13.0) 9.2
52-week high/low 69.9p 49.6p

Business description

Foxtons Group is London’s leading and most widely recognised estate agency. It operates from a network of interconnected branches offering a range of residential-related services, which are split into three separate revenue streams: sales, lettings and mortgage broking.

Next events

AGM

7 May 2025

Capital markets day

4 June 2025

Analyst

Andy Murphy
+44 (0)20 3077 5700

Foxtons Group is a research client of Edison Investment Research Limited

Note: PBT and EPS include amortisation of acquired intangibles and exceptional items (ie diluted company definition).

Year end Revenue (£m) PBT (£m) EPS (p) DPS (p) P/E (x) Yield (%)
12/23 147.1 7.9 3.21 0.90 17.8 1.6
12/24 163.9 17.5 4.93 1.17 11.6 2.0
12/25e 176.5 18.2 5.26 1.84 10.9 3.2
12/26e 183.5 23.4 6.54 2.29 8.8 4.0

Healthy Q1 trading driven by Sales

Foxtons’ Q1 group revenue increased by 24% to £44.1m, with Sales being the primary driver, supported by more modest growth in Lettings and Financial Services. The largest division, Lettings, grew revenue by 5% (or £1.3m) to £25.2m, mainly due to including the October 2024 acquisitions. It also benefited from higher property management revenues and increased long-term lets, offset by volatility in renewals and lower interest income on client deposits. The Sales division increased revenue by 73% (or £6.9m), largely driven by organic growth, with the Stamp Duty change pulling volumes forward from Q2, with some additional benefit from M&A. The Financial Services division increased revenue by 7%, supported by the new purchase revenue and partially offset by lower refinance activity.

Capital markets day to set out revised growth strategy

On 17 April, Foxtons announced that it intends to hold a capital markets day at the London Stock Exchange on 4 June to present and discuss its latest strategy for growth. This is likely to build on the existing strategy and targets that have been largely met and, in the case of Sales’ market share, exceeded. Furthermore, the medium-term profit target, which was increased from £25–30m to £28–33m to reflect the exclusion of amortisation, is likely to be reviewed and potentially revised upwards considering the success to date and the fact that we believe Foxtons is likely to hit the lower end of the target range as early as FY26.

Share buyback and largely unchanged forecasts

Following the Q125 results statement, we have retained existing revenue and adjusted operating profit figures, but raised EPS modestly due to the share buyback. Q1 trading was robust, especially in Sales, but Q2 will no doubt be initially affected as the Stamp Duty changes saw volumes pulled forward into Q1, and the under-offer pipeline was down c 10% at the start of Q2. However, we have reflected the £3m share buyback, which implies that year-end net debt increases by a similar figure, from £5.4m to £8.4m, leaving sufficient upside for M&A.

General disclaimer and copyright

This report has been commissioned by Foxtons Group and prepared and issued by Edison, in consideration of a fee payable by Foxtons Group. Edison Investment Research standard fees are £60,000 pa for the production and broad dissemination of a detailed note (Outlook) following by regular (typically quarterly) update notes. Fees are paid upfront in cash without recourse. Edison may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.

Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained in this report represent those of the research department of Edison at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.

Exclusion of Liability: To the fullest extent allowed by law, Edison shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out or in connection with the access to, use of or reliance on any information contained on this note.

No personalised advice: The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Edison’s solicitation to effect, or attempt to effect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.

Investment in securities mentioned: Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison's policies on personal dealing and conflicts of interest.

Copyright 2025 Edison Investment Research Limited (Edison).

Australia

Edison Investment Research Pty Ltd (Edison AU) is the Australian subsidiary of Edison. Edison AU is a Corporate Authorised Representative (1252501) of Crown Wealth Group Pty Ltd who holds an Australian Financial Services Licence (Number: 494274). This research is issued in Australia by Edison AU and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. Any advice given by Edison AU is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument.

New Zealand

The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are “wholesale clients” for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a “personalised service” and, to the extent that it contains any financial advice, is intended only as a “class service” provided by Edison within the meaning of the FAA (i.e. without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision.

United Kingdom

This document is prepared and provided by Edison for information purposes only and should not be construed as an offer or sol icitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document.

This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.

United States

Edison relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Edison does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.

London │ New York │ Frankfurt

20 Red Lion Street

London, WC1R 4PS

United Kingdom

More on Foxtons Group

View All

Latest from the Real Estate sector

View All Real Estate content

Research: Healthcare

Recce Pharmaceuticals — Funding secured to start Phase III pivotal trials

Recce is raising up to A$15.8m in equity fundraising through a now-completed A$5.0m share placement and an entitlement offer for remaining shareholders that could raise up to an additional A$10.8m in gross proceeds. Both rounds of financing are priced at A$0.28 per new share. We anticipate the total funding should support Recce’s operations into Q226 (Q4 CY25) as its near-term focus lies on advancing R327 topical gel (R327G) through registration-enabling pivotal studies. We expect Recce to start a registrational Indonesian Phase III study of R327G for the treatment of diabetic foot infections (DFIs) in the coming weeks. We now obtain an rNPV valuation of A$615.1m and our per-share valuation adjusts to A$2.51 per share (vs A$2.68 previously), reflecting the increase in shares outstanding after the placement.

Continue Reading

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free